<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28875730</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8352</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Expert review of molecular diagnostics</Title>
          <ISOAbbreviation>Expert Rev Mol Diagn</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Liquid biopsy for brain tumors.</ArticleTitle>
        <Pagination>
          <StartPage>943</StartPage>
          <EndPage>947</EndPage>
          <MedlinePgn>943-947</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14737159.2017.1374854</ELocationID>
        <Abstract>
          <AbstractText>Minimally invasive methods will augment the clinical approach for establishing the diagnosis or monitoring treatment response of central nervous system tumors. Liquid biopsy by blood or cerebrospinal fluid sampling holds promise in this regard. Areas covered: In this literature review, the authors highlight recent studies describing the analysis of circulating tumor cells, cell free nucleic acids, and extracellular vesicles as strategies to accomplish liquid biopsy in glioblastoma and metastatic tumors. The authors then discuss the continued efforts to improve signal detection, standardize the liquid biopsy handling and preparation, develop platforms for clinical application, and establish a role for liquid biopsies in personalized medicine. Expert commentary: As the technologies used to analyze these biomarkers continue to evolve, we propose that there is a future potential to precisely diagnose and monitor treatment response with liquid biopsies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Shankar</LastName>
            <ForeName>Ganesh M</ForeName>
            <Initials>GM</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Neurosurgery , Massachusetts General Hospital , Boston , MA , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Balaj</LastName>
            <ForeName>Leonora</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Neurosurgery , Massachusetts General Hospital , Boston , MA , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stott</LastName>
            <ForeName>Shannon L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>b Cancer Center, Department of Medicine , Massachusetts General Hospital , Boston , MA , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nahed</LastName>
            <ForeName>Brian</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>b Cancer Center, Department of Medicine , Massachusetts General Hospital , Boston , MA , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carter</LastName>
            <ForeName>Bob S</ForeName>
            <Initials>BS</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Neurosurgery , Massachusetts General Hospital , Boston , MA , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA069246</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UH3 TR000931</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>09</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Expert Rev Mol Diagn</MedlineTA>
        <NlmUniqueID>101120777</NlmUniqueID>
        <ISSNLinking>1473-7159</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074166">Circulating MicroRNA</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000074141">Circulating Tumor DNA</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074166" MajorTopicYN="N">Circulating MicroRNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074141" MajorTopicYN="N">Circulating Tumor DNA</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055354" MajorTopicYN="N">Exosomes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073890" MajorTopicYN="N">Liquid Biopsy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Liquid biopsy</Keyword>
        <Keyword MajorTopicYN="Y">brain tumors</Keyword>
        <Keyword MajorTopicYN="Y">cell free tumor DNA</Keyword>
        <Keyword MajorTopicYN="Y">circulating tumor cells</Keyword>
        <Keyword MajorTopicYN="Y">exosome</Keyword>
      </KeywordList>
      <CoiStatement><b>Declaration of interest</b> The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28875730</ArticleId>
        <ArticleId IdType="mid">NIHMS948207</ArticleId>
        <ArticleId IdType="pmc">PMC5856481</ArticleId>
        <ArticleId IdType="doi">10.1080/14737159.2017.1374854</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Peca C, Pacelli R, Elefante A, et al.  Early clinical and neuroradiolo-gical worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecro-sis? Clin Neurol Neurosurg. 2009;111(4):331–334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19117668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neagu MR, Huang RY, Reardon DA, et al.  How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015;17(4):343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25749847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagle N, Grabiner BC, Van Allen EM, et al.  Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426–1433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4564868</ArticleId>
            <ArticleId IdType="pubmed">25295501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel AP, Tirosh I, Trombetta JJ, et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396–1401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4123637</ArticleId>
            <ArticleId IdType="pubmed">24925914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siravegna G, Marsoni S, Siena S, et al.  Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28252003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016;10(3):374–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528969</ArticleId>
            <ArticleId IdType="pubmed">26897752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pratt ED, Huang C, Hawkins BG, et al.  Rare cell capture in micro-fluidic devices. Chem Eng Sci. 2011;66(7):1508–1522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3082151</ArticleId>
            <ArticleId IdType="pubmed">21532971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sullivan JP, Nahed BV, Madden MW, et al.  Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4(11):1299–1309. This study reports a microfluidic approach to isolating circulating tumor cells in blood allowing the authors to detect these macromolecules in 39% of patients with glioblastoma, primarily in those with the mesenchymal profile.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4221467</ArticleId>
            <ArticleId IdType="pubmed">25139148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller C, Holtschmidt J, Auer M, et al.  Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6(247):247–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25080476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao F, Cui Y, Jiang H, et al.  Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016;7(44):71330–71340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5342081</ArticleId>
            <ArticleId IdType="pubmed">27517490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohr JG, Adalsteinsson VA, Cibulskis K, et al.  Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32(5):479–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4034575</ArticleId>
            <ArticleId IdType="pubmed">24752078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maheswaran S, Haber DA. Ex vivo culture of CTCs: an emerging resource to guide cancer therapy. Cancer Res. 2015;75(12):2411–2415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4470788</ArticleId>
            <ArticleId IdType="pubmed">25998619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bettegowda C, Sausen M, Leary RJ, et al.  Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4017867</ArticleId>
            <ArticleId IdType="pubmed">24553385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang TY, Piunti A, Lulla RR, et al.  Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017;5(1):28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5392913</ArticleId>
            <ArticleId IdType="pubmed">28416018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Huan W, Zuo H, et al.  Alu methylation serves as a biomarker for non-invasive diagnosis of glioma. Oncotarget. 2016;7(18):26099–26106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5041967</ArticleId>
            <ArticleId IdType="pubmed">27028997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Springer S, Zhang M, et al.  Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA. 2015;112(31):9704–9709. This study demonstrates that cell-free tumor DNA could be detected by targeted sequencing in the CSF of patients with tumors adjacent to a cisternal or ventricular space.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4534284</ArticleId>
            <ArticleId IdType="pubmed">26195750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skog J, Wurdinger T, van Rijn S, et al.  Glioblastoma microvesi-cles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–1476. These authors report that tumor-specific mRNA and miRNA could be detected in serum exosome preparations obtained from patients with glioblastoma. Furthermore, these tumor-derived exosomes could transfer mRNA to glioma cells and stimulate proliferation.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3423894</ArticleId>
            <ArticleId IdType="pubmed">19011622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noerholm M, Balaj L, Limperg T, et al.  RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer. 2012;12:22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3329625</ArticleId>
            <ArticleId IdType="pubmed">22251860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen WW, Balaj L, Liau LM, et al.  BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cere-brospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2:109. This study reports a sensitive method for detecting mutant IDH1 transcripts in extracellular vesicle preparations from CSF.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3732870</ArticleId>
            <ArticleId IdType="pubmed">23881452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Figueroa JM, Skog J, Akers J, et al.  Detection of wtEGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017 Apr 27; doi: 10.1093/neuonc/nox085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nox085</ArticleId>
            <ArticleId IdType="pmc">PMC5737576</ArticleId>
            <ArticleId IdType="pubmed">28453784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manda SV, Kataria Y, Tatireddy BR, et al.  Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. J Neurosurg. 2017:1–11. doi: 10.3171/2016.11.JNS161187. [Epub ahead of print]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2016.11.JNS161187</ArticleId>
            <ArticleId IdType="pubmed">28574310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akers JC, Ramakrishnan V, Kim R, et al.  MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One. 2013;8(10):78115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3804457</ArticleId>
            <ArticleId IdType="pubmed">24205116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akers JC, Hua W, Li H, et al.  A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. Oncotarget. 2015;6(25):20829–20839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4673232</ArticleId>
            <ArticleId IdType="pubmed">26246487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graner MW, Alzate O, Dechkovskaia AM, et al.  Proteomic and immunologic analyses of brain tumor exosomes. Faseb J. 2009;23(5):1541–1557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2669426</ArticleId>
            <ArticleId IdType="pubmed">19109410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao H, Chung J, Balaj L, et al.  Protein typing of circulating micro-vesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012;18(12):1835–1840. This study describes an ultrasensitive microfluidic platform for the detection of tumor-specific proteins on the surface of microvesicles released from glioblastoma.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3518564</ArticleId>
            <ArticleId IdType="pubmed">23142818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Skog J, Hsu CH, et al.  Microfluidic isolation and tran-scriptome analysis of serum microvesicles. Lab Chip. 2010;10(4):505–511. This study describes the microfluidic enrichment of microvesi-cles for analysis of RNA. By reducing the number of centrifugation steps involved with prior techniques, the approach described here allows for preserving the integrity of microvesicles.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3136803</ArticleId>
            <ArticleId IdType="pubmed">20126692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014;14(3):195–208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4350779</ArticleId>
            <ArticleId IdType="pubmed">24566916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao H, Chung J, Lee K, et al.  Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015;6:6999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4430127</ArticleId>
            <ArticleId IdType="pubmed">25959588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20847746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akers JC, Ramakrishnan V, Yang I, et al.  Optimizing preservation of extracellular vesicular miRNAs derived from clinical cerebrospinal fluid. Cancer Biomark. 2016;17(2):125–132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4992418</ArticleId>
            <ArticleId IdType="pubmed">27062568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fritz JV, Heintz-Buschart A, Ghosal A, et al.  Sources and functions of extracellular small RNAs in human circulation. Annu Rev Nutr. 2016;36:301–336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5479634</ArticleId>
            <ArticleId IdType="pubmed">27215587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akers JC, Ramakrishnan V, Nolan JP, et al.  Comparative analysis of technologies for quantifying extracellular vesicles (EVs) in clinical cerebrospinal fluids (CSF) PLoS One. 2016;11(2):0149866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4763994</ArticleId>
            <ArticleId IdType="pubmed">26901428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li M, Chen WD, Papadopoulos N, et al.  Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27(9):858–863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2847606</ArticleId>
            <ArticleId IdType="pubmed">19684580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shankar GM, Francis JM, Rinne ML, et al.  Rapid intraoperative molecular characterization of glioma. JAMA Oncol. 2015;1(5):662–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872045</ArticleId>
            <ArticleId IdType="pubmed">26181761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diehl F, Schmidt K, Choti MA, et al.  Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990. The authors demonstrate here that targeted sequencing could detect somatic tumor mutations in circulating nucleic acid preparations from plasma of patients with colorectal cancer. Furthermore, the concentration of circulating tumor DNA correlated with systemic tumor burden suggesting that this approach could be used to monitor treatment response.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2820391</ArticleId>
            <ArticleId IdType="pubmed">18670422</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
